Researchers are increasingly focused on retatrutide, a innovative treatment developed by Eli Lilly, as a possible advance in body reduction . Unlike many earlier approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, chemicals that affect satiety and blood sugar regulati… Read More